Related references
Note: Only part of the references are listed.Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
Tim J. Kruser et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Comparison of immunohistochemistry and DNA sequencing for the detection of IDH1 mutations in gliomas
Yingjie Zou et al.
NEURO-ONCOLOGY (2015)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading
David N. Louis et al.
BRAIN PATHOLOGY (2014)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes
Marianne Labussiere et al.
NEUROLOGY (2014)
A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma
Aurelie Catteau et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2014)
The Definition of Primary and Secondary Glioblastoma
Hiroko Ohgaki et al.
CLINICAL CANCER RESEARCH (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
Moving toward molecular classification of diffuse gliomas in adults
Brett J. Theeler et al.
NEUROLOGY (2012)
IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee
M. Preusser et al.
CLINICAL NEUROPATHOLOGY (2011)
IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors
Marta Mellai et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy?
Marianne Labussiere et al.
ONCOLOGIST (2010)
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Takuya Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients
Yukihiko Sonoda et al.
CANCER SCIENCE (2009)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Marc Sanson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Koichi Ichimura et al.
NEURO-ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Genetic pathways to glioblastoma:: A population-based study
H Ohgaki et al.
CANCER RESEARCH (2004)
Share Paper
